Skip to content
Review Open access

Hypoxia-inducible factor as a master switch in ocular neovascularization: overcoming anti-VEGF resistance and exploring therapeutic prospects

Sep 2026 · Journal of Translational Medicine · 0 citations

TL;DR

This review summarizes HIF-targeted strategies at the molecular, clinical, and emerging therapeutic levels, with a focus on the translational progress of lead candidates such as 32-134D and PX-478.

Abstract

Hypoxia-inducible factor (HIF) is a key driver of ocular neovascular diseases. We systematically discuss its regulatory mechanisms and pathological roles in diabetic retinopathy (DR), retinopathy of prematurity (ROP), and neovascular age-related macular degeneration (nAMD). Upon integration of diverse upstream stimuli—including hypoxia, hyperglycemia, oxidative stress, and inflammatory signals—HIF orchestrates a downstream effector network that drives aberrant neovascularization, vascular leakage, fibrotic remodeling, and neuroretinal degeneration. Current anti-vascular endothelial growth factor (Anti-VEGF) therapies, which block only a single downstream factor, are constrained by inadequate response and resistance. Therefore, pharmacological targeting of the upstream “master switch” HIF represents a promising strategy for achieving broader therapeutic efficacy. In this review, we summarize HIF-targeted strategies at the molecular, clinical, and emerging therapeutic levels,with a focus on the translational progress of lead candidates such as 32-134D and PX-478. Furthermore, the present review highlights the dual role of HIF in physiological vascular development and pathological neovascularization, emphasizing that precise regulation of timing, cell type and microenvironment is critical for therapeutic success. Finally, the limitations of current HIF-targeted therapies and future directions are discussed. Collectively, these insights may support the development of more precise and effective therapies for ocular neovascular diseases.

Read PDF

Similar papers

Review Open access 2026

From bench to bedside: translational advances, therapeutic targets, and delivery strategies in diabetic retinopathy.

Diabetic retinopathy (DR) is a leading cause of preventable blindness in adults of working age. Anti-vascular endothelial growth factor (anti-VEGF) therapy is the reference standard for diabetic macular edema (DME), yet in randomized cohorts, approximately 30-40% of DME eyes still show central macular thickening after...

Hai Chen, Wei Chen · 0 citations
Review Open access Nov 2026

Angiopoietin-2 in Retinal Vascular Fibrosis: Mechanisms and Therapeutic Implications for Diabetic Retinopathy.

Retinal vascular fibrosis is a pathological hallmark of advanced diabetic retinopathy (DR), marking the transition from reversible vascular dysfunction to irreversible structural damage. Emerging evidence has established angiopoietin-2 (Ang-2) as a crucial initiating factor in retinal vascular fibrosis. In the diabetic...

Xin-Ping Yan, Ying-Shi Zou, Tian-Yi Luo et al. · 0 citations
Nov 2026

Endothelium-targeted myc silencing suppresses pathological ocular neovascularization.

Ocular neovascularization (NV) causes blindness, yet anti-VEGF therapy has limited efficacy. Myc controls endothelial cell (EC) proliferation and activation, however, its pathological role in ocular NV and therapeutic value remain unclear. In this study, we found that Myc was markedly upregulated in neovascular ECs (NV...

Bo Tang, Quan Zhang, Ya-Nan He et al. · 0 citations
Review Open access Oct 2026

Evolution of vascular normalization strategies: from anti-angiogenesis to remodeling the tumor microenvironment

Although anti-angiogenic therapy has been widely used in the treatment of solid tumors, angiogenesis inhibition alone frequently induces acquired resistance and exacerbates tumor hypoxia, paradoxically promoting tumor progression. The concept of tumor vascular normalization has offered a new perspective to address this...

Qiang Huang, Yu-Jing Guo, Shan-Yu Yin et al. · 0 citations
Review Open access Sep 2026

Fibrotic Remodeling in Retinal Vascular Diseases: Cellular Origins, Molecular Mechanisms, and Therapeutic Perspectives

Highlights What are the main findings? This review summarizes the cellular and molecular mechanisms of ocular fibrosis. This review also summarizes current therapies and their limitations, as well as potential treatments in pre-clinical studies and clinical trials. What are the implications of the main findings? Unders...

Jia-Yu Ning, Brian Wang, M. Yamamoto et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.